Capecitabine (Xeloda)

DRUG15 trials

Sponsors

Dartmouth-Hitchcock Medical Center, Translational Oncology Research International, Odense University Hospital, James A. Haley Veterans Administration Hospital, Rambam Health Care Campus

Conditions

AdenocarcinomaAdenocarcinoma Clear CellBiliary Tract Cancer (BTC)Breast CancerC04.588.274.476.411.307Cancer of LiverCarcinoma, Squamous CellColorectal Cancer

Phase 1

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

CompletedNCT00153881

Dartmouth-Hitchcock Medical CenterEsophageal Neoplasms

Start: 2000-02-29End: 2013-09-30Updated: 2014-11-13

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

TerminatedNCT00216437

James A. Haley Veterans Administration HospitalCancer of Liver

Start: 2004-12-31End: 2007-03-31Target: 30Updated: 2007-11-12

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

CompletedNCT00316420

Swedish Medical CenterPancreatic Cancer

Start: 2003-12-31End: 2009-08-31Updated: 2010-03-08

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

TerminatedNCT00354523

M.D. Anderson Cancer CenterSolid Tumor, Thyroid Cancer

Start: 2004-12-31End: 2013-08-31Updated: 2014-12-17

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

TerminatedNCT00368329

Stanford UniversityAdenocarcinoma, Carcinoma, Squamous Cell, Esophageal Cancer +1

Start: 2006-06-30End: 2009-03-31Updated: 2012-07-16

Phase 2

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

CompletedNCT00203411

Translational Oncology Research InternationalColorectal Cancer

Start: 2006-03-31End: 2011-03-31Updated: 2017-02-06

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

CompletedNCT00212615

Odense University HospitalC04.588.274.476.411.307

Start: 2004-02-29End: 2008-10-31Updated: 2020-11-06

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Rambam Health Care CampusAdenocarcinoma Clear Cell

Start: 2003-12-31End: 2005-09-30Target: 45Updated: 2006-01-04

Xeloda and Bevacizumab to Treat Rectal Cancer

CompletedNCT00847119

Institut Català d'OncologiaRectal Cancer

Start: 2007-09-30End: 2015-02-28Updated: 2017-08-29

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

TerminatedNCT07012330

Erasmus Medical CenterNeuroendocrine (NE) Tumors

Start: 2007-03-01End: 2015-12-31Updated: 2025-06-10

Phase 3

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

TerminatedNCT00440622

Hellenic Oncology Research GroupBreast Cancer

Start: 2003-04-30End: 2008-11-30Updated: 2013-02-13

Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer

CompletedNCT01308190

Corporacion Parc TauliRectal Cancer

Start: 2010-08-31End: 2021-10-31Updated: 2021-11-23

Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)

Not yet recruitingNCT06450574

Corporacion Parc TauliRectal Cancer Stage I

Start: 2024-10-31End: 2027-10-31Target: 106Updated: 2024-06-10

Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

Not yet recruitingNCT07745296

UNICANCERBiliary Tract Cancer (BTC)

Start: 2027-01-02End: 2033-07-02Target: 990Updated: 2026-08-04

Phase 4

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

TerminatedNCT00216424

James A. Haley Veterans Administration HospitalColorectal Cancer

Start: 2005-02-28End: 2007-01-31Target: 40Updated: 2007-11-12

Related Papers

Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study).

2026-04-23

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial.

2025-07-015 citations

Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).

2022-10-0841 citations

Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study.

Journal of Clinical Oncology2022-06-014 citations

Non-inferiority multicenter prospective randomized controlled study of rectal cancer T<sub>2</sub>-T<sub>3s</sub> (superficial) N<sub>0</sub>, M<sub>0</sub> undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME).

2017-12-1221 citations

Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.

2015-02-2617 citations

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.

2014-08-0215 citations

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

2013-07-1762 citations